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M. Joglekar, J. Ware, T. K. Gartner. FeCl3-induced thrombus formation in murine 
inferior vena cava requires platelets, platelet receptor GPIb-IX and von Willebrand 
factor.  XXII Congress July 11-16, 2009. International Society on Thrombosis and 
Haemostasis. Major Professor: T. Kent Gartner, PhD. 
Venous thromboembolism (VTE) is the leading cause of death from 
cardiovascular disease. Despite the importance of the glycoprotein (GP) Ib-IX/von 
Willebrand factor (VWF) axis in arterial thrombosis, its requirement in venous, not 
venule thrombosis has not been tested. We evaluated FeCl3-induced thrombus formation 
in inferior vena cava (IVC) of mice. We first established FeCl3 injury conditions (20% 
FeCl3, 10 minutes) requiring platelets for IVC occlusion as confirmed by a lack of 
occlusion in severely thrombocytopenic (less than 23% circulating platelet count) mice 
(n=7) and stable occlusion in control animals.  
Using similar injury conditions, no IVC occlusion was observed using platelet 
GPIbα-deficient animals (n=6), a model of human Bernard-Soulier syndrome (BSS). 
Transgenic IL-4R/GPIbα mice were studied to determine if the absence of IVC occlusion 
in the mouse model of BSS was caused by extracellular GPIbα deficiency or by other 
platelet abnormalities associated with BSS phenotype. IL-4R/GPIbα mice lack murine 
GPIbα, but express a transgenic fusion protein compound of an extracellular domains of 
human IL-4 receptor fused to the transmembrane and cytoplasmic domains of human 
GPIbα ; an ameliorated form of mouse BSS lacking macrothrombocytopenia. No 
occlusion was observed in the IVC of IL-4R/GPIbα mice (n=8), just as observed with the 
murine model of BSS. VWF-deficient mice were also studied and failed to occlude in 
response to FeCl3 treatment (n=7).  
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These data establish experimental conditions for FeCl3-induced thrombus 
formation in the IVC that is platelet, platelet receptor GPIbα and VWF-dependent despite 
the low venous flow rate in the IVC. Also unlike venules, thrombus formation in IVC’s is 
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CHAPTER 1:  INTRODUCTION 
Venous thromboembolism (deep vein thrombosis (DVT) and/or pulmonary 
embolism, PE) is a leading cause of morbidity and mortality in the United States. VTE 
causes about 300,000 deaths annually. VTE is a multifactorial disease with both 
environmental and genetic causal factors [1]. The frequency of VTE increases with 
increasing age. Therefore the importance of VTE increases as the population ages. The 
pathogenesis of VTE is poorly understood. This in turn has increased the importance of 
studying the basis of deep vein thrombosis.  
Thrombus formation occurs by different mechanisms in arteries and veins. 
Thrombus formation in arteries involves platelet interactions with the vessel wall and is 
shear dependent [2]. Following vascular injury, collagen in the subendothelium is 
exposed and subsequently plasma von Willebrand factor (VWF) binds to the collagen and 
is immobilized on the subendothelium. The initial platelet tethering to the injured site is 
mediated by the interaction of immobilized VWF with platelet receptor GPIbα [3]. 
Downstream signaling through GPIb results in thromboxane A2 (TxA2) production 
followed by platelet dense granule secretion which releases ADP. Both TxA2 and ADP 
can activate the integrin αIIbβ3 which mediates platelet aggregation and spreading [4]. 
ADP activates the nearby platelets thereby facilitating the platelet-platelet interactions 
and increasing the recruitment of more platelets to the site of injury.  
Venous circulation operates at low shear (low shear rate, e.g. 50 s
-1
 – 100 s
-1
) and 
it is generally believed that thrombus formation in this bed is less dependent on platelets 
or shear-dependent interactions with the vessel walls. VTE is thought to arise from 
changes in the vessel due to stasis [5], inflammation of the vein wall [6], or coagulation 
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and fibrinolytic abnormalities. In fact, some scientists consider inflammation and/or 
coagulation to be the initial steps for thrombus formation in veins. Thrombus formation 
in venules ( shear rate- 150 sec
-1
 – 200 sec
-1 
) has been studied and is shown to be VWF 
dependent but does not absolutely require GPIb [7].Compared to arteries, shear rates in 
veins are much lower [8]. Shear rates have a profound effect on the thrombus formation. 
Although in vitro studies have shown that VWF can mediate platelet-vessel wall 
interactions even at low shear rates [9], the contribution of platelets, GPIbα and VWF in 
the venous circulation (not venules) has not been characterized. Thus, the objective of 
this project was to characterize the requirement of platelets, GPIbα and VWF for in vivo 
venous thrombus formation in mice in reponse to FeCl3- induced injury. 
 To study the contribution of platelet-vessel wall interactions in VTE thrombus 
formation in murine inferior vena cava (IVC) was studied in response to ferric chloride-
induced injury. The results of this study will establish whether or not thrombus formation 
under conditions of venous shear rate can be dependent on platelets, platelet receptor 
GPIb-IX-V and VWF. 
1.1. Deep Vein Thrombosis 
There are two types of veins in the leg; superficial veins and the deep veins. The 
superficial veins lie just below the skin and the deep veins are located deep within the 
muscles. In deep vein thrombosis, a blood clot forms in the deep veins of leg. The clot 
can be formed due to vascular damage or slow or no blood flow (stasis). Sometimes the 
clot breaks off and travels to the lungs (pulmonary embolism) via venous circulatory 
system. This process is known as venous thromboembolism (VTE). Risk factors of DVT 
are age, surgery, trauma, and immobility [1]. People traveling long distances are at risk of 
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DVT due to immobility in automobiles and aircrafts. The symptoms of DVT are related 
in part to the limited blood flow to the heart, and include pain in the leg, swelling due to 
inflammation, warmth and redness. 
1.2. Overview of Blood Coagulation/ Haemostasis 
Blood coagulation or haemostasis is a complex process that regulates and stops 
bleeding at the site of vascular injury. Coagulation process depends upon two pathways: 
Tissue factor pathway (extrinsic) and contact activation (intrinsic) pathway. 
Conventionally it is accepted that the initiation of the coagulation pathway is triggered by 
the extrinsic pathway and the intrinsic pathway amplifies the cascade. These two 
pathways ultimately lead to fibrin formation (common pathway) that helps to stop 
bleeding by forming a clot consisting of fibrin and platelets (Fig.1). The two pathways 
involve activation of an inactive enzyme or zymogen (protease) to its active form which 
further catalyzes the next reaction in the cascade. The end result is formation of a fibrin 
mesh which helps to hold platelet plug together. 
1.2.1. Tissue factor pathway (extrinsic)  
Tissue factor pathway is initiated upon vascular injury/ trauma. Upon the vascular 
injury, circulating FVII (inactive) comes in contact with the tissue factor (TF) expressed 
by vascular smooth muscle cells. Under normal conditions, the TF expressed by the 
vascular smooth muscle cells is masked or separated by the endothelial cells, but after the 
endothelial cell layer is damaged due to injury, the TF is exposed to the flowing blood 
and binds to the circulating FVII. Binding of the TF to the FVII forms TF:FVII complex 
(active). Activated TF:FVII complex activates FIX and FX. Constitutive activation of the 
TF:FVII complex can prove to be dangerous and thus immediately after the TF:FVII 
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complex activates FX, the TF:FVII complex is inhibited by the tissue factor pathway 
inhibitor (TFPI). The activated FX (FXa) along with its cofactor FVa forms the 
prothrombinase complex. Prothrombinase complex further converts prothrombin to 
thrombin. Further thrombin activates FV and FVIII. FVIIIa is a cofactor for activation of 
FIX and so the cycle continues. 
1.2.2. Contact activation (intrinsic) pathway 
 This pathway starts with formation of the primary complex on the collagen by a 
protein called ‘high molecular weight kininogen (HMWK), prekallikrein and FXII 
(Hageman factor). In this pathway, prekallikrein is converted to kallikrein and FXII is 
converted to its active form (FXIIa). FXIIa activates FXI (FXIa). FXIa in turn activates 
FIX. FIXa with its cofactor FVIIIa, activates FX to FXa. This explains the amplifying 
characteristic of the intrinsic pathway. The extrinsic and intrinsic pathways converge at 
this point into the common pathway. 
1.2.3. Common pathway 
In this pathway, the thrombin generated by the intrinsic and extrinsic pathway 
converts fibrinogen to fibrin, which is the building block of the haemostatic plug or a 
clot.   
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  Fig.1: Coagulation cascade (normal haemostasis) 
1.3. Platelets 
Platelets are a critical component of the blood because of their fundamental role 
in hemostasis and thrombosis. Platelets are anucleate hematopoietic cells. Human 
platelets are 2.0-5.0 µm in diameter and 0.5 µm in thickness. Normal range of platelet 
number in blood is 150-400 Χ 10
9
 per liter [10]. Platelets function as cellular “zymogens” 









 Platelet structure includes a plasma membrane, the cytoskeleton, and the 
cytoplasm [10]. 
1.3.1a Plasma membrane 
The plasma membrane of the platelets consists of a glycocalyx. The exterior 
surface is a very dynamic structure which serves as the site for the first contact in 
response to the changes in vascular system. The glycocalyx is mainly composed of the 
glycoprotein receptors which are necessary for platelet adhesion to vascular surface and 
to promote platelet aggregation and interaction with the other blood components. The 
plasma membrane is made up of the lipid bilayer.  
1.3.1b Cytoskeleton 
The cytoskeleton consists of microtubules and microfilaments. The microtubules 
are present in bundles ranging from 3 to 24 and are present very close to the plasma 
membrane. The major protein constituent of microtubules is tubulin. Microfilaments are 
made up of globular protein called actin. These filaments play a vital role in platelet 
physiology. Microfilaments are present near both the plasma membrane and are the major 
constituent of the cytoplasmic cytoskeleton. The microfilaments associated with the 
plasma membrane serve as matrix on which the organelles are suspended. The 
cytoskeleton helps the secretion of the contents from the α-granules and dense bodies to 







Platelet cytoplasm contains α-granules, dense bodies, lysosomes, mitochondria.  
α-granules- There are 40 to 80 α-granules per platelet. They are round to oval shaped, 
surrounded by a membrane and are about 200 to 500 nm in diameter. The granules 
contain more than two dozen different proteins which play a role in hemostasis, 
thrombosis and wound healing such as adhesive proteins, chemokines, cytokines, 
coagulation factors, angiogenic regulatory proteins and fibrinolytic proteins etc.  
Dense bodies- Dense bodies are smaller and less numerous than the α-granules. Dense 
bodies are spherical and covered with an enclosing membrane. Some dense bodies can 
have whiplike extensions. On an average, there are 4-8 dense bodies in a platelet.  Dense 
bodies are rich in adenine nucleotides such as ATP and ADP, serotonin, calcium, 
magnesium and pyrophosphates.  
Mitochondria- There are very few mitochondria present in a platelet. These are very 
simple structurally and are the sites of oxidation in the platelets.  
Lysosomes- Human platelets have few lysosomes (minimum 0 to 1, maximum 3). They 
have 13 acid hydrolases and cathepsin D and E and CD36 (a lysosomal membrane 
protein). The function of platelet lysosomes is not clear but they release their contents 
after platelet activation. Platelet lysosomes do not engulf bacteria as do phagocytes so 







1.3. 2.Platelet Receptor Glycoprotein IB-IX-V  
The glycoprotein Ib-IX-V complex is an important platelet membrane adhesion 
receptor that participates in both haemostasis and thrombosis. As shown in figure 2, the 
GPIb-IX complex is made up of the following four different gene products: GPIbα (~ 135 
kDa), which is linked to GPIbβ (~25 kDa) by disulfide bonds, GPIX (~22 kDa) and GPV 
(~82 kDa). The GPIX and GPV components are attached to the GPIb by non-covalent 
interactions. These four subunits make the intact GPIb-IX-V complex as shown in figure 
2. This complex is expressed on the platelet surface in the ratio of 2:2:2:1 for GPIbα: 
GPIbβ: GPIX: GPV. About 25,000 GPIb-IX-V complexes are constitutively expressed on 
the platelet surface [3]. In humans, GPIb, IX, and V  are type I membrane spanning 
subunit having a N-terminal ligand binding domain, a transmembrane region and 
cytoplasmic tail as shown in figure 2.  The N- terminal domain of the GPIbα contains the 




Fig. 2: Glycoprotein Ib-IX-V complex 




1.3.2a Functions of GPIb-IX-V 
The main functions of the platelet receptor GPIb-IX-V complex are as follows: 
1. Regulation of platelet adhesion to the sub-endothelial layer and 
leukocytes. 
2. Assemble/procoagulant activity on activated platelets. 
3. Initiate outside-in signaling that activates platelets and platelet αIIbβIII 
resulting in platelet aggregate formation at the site of platelet adhesion to the 
damaged endothelium. (Topographical interactions) [11]. 
1.3.3. Ligands of GPIb-IX-V complex 
VWF is the major ligand for the receptor GPIb. Amongst the other ligands 
includes thrombospondin (TSP), thrombin and P-selectin. There are a variety of non-
physiological ligands for this receptor such as snake venoms toxins and bacteria [12]. 
1.3.3.1 von Willebrand factor (major ligand) 
Interaction of soluble (that which circulates in the blood) VWF with its receptor 
GPIb is shear dependent. At all arterial shear rates, the GPIbα-VWF interaction is 
required for platelet adhesion to the damaged vasular surface [13]. The interaction of 
GPIbα and VWF has been studied by crystallography. VWF binds to the N-terminal 
ligand binding region of GPIbα by its A1 domain [14].  GPIbα residues have a direct 
contact with the VWF A1 domain and are clustered toward the N-terminal and C-
terminal ends of the ligand binding region [12]. VWF is the major ligand of glycoprotein 
receptor Ibα. Binding of VWF to its receptor GPIbα is essential, as it elicits the initial 
step for the platelets to become stationary on the injured vascular wall and thus for the 
thrombus growth. Binding of VWF to GPIbα also triggers signaling events that lead to 
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platelet activation, as well as cytoskeletal changes that regulate platelet spreading, shape 
change, secretion and aggregation. Under normal circumstances, soluble VWF does not 
bind stably to GPIbα on platelets suspension [12]. Normal interaction of GPIbα with 
VWF requires a trigger which can be pathological shear stress, immobilization of VWF 
on collagen or other subendothelial components. After VWF-mediated adhesion of 
platelets to the damaged endothelium, secreted VWF can bind to active αIIbβ3 in the 
growing aggregate thereby facilitating hemostasis or thrombus formation [12]. 
1.3.3.2 Thrombospondin 
Thrombospondin-1(TSP) is a recently identified ligand for GPIb-IX-V. TSP binds 
GPIb-IX-V at high shear rate and is able to support platelet adhesion in absence of VWF 
[15].  
1.3.3.3 Thrombin 
Thrombin binds to the α-subunit of GPIb at the Tyr276 residue, an interaction 
important for normal physiological hemostasis and thrombosis. In vivo thrombus 
formation was studied for both laser induced injury mouse model and FeCl3 induced 
injury model using the transgenic mice expressing the normal human GPIbα (hTg
WT
) 
subunit and a mutant human GPIbα containing a Phe substitution for the Tyr276 
(hTg
Y276F
). Delayed thrombus formation in the mutant mice (hTg
Y276F
) in the FeCl3 
induced injury and less stable thrombus in laser induced injury demonstrates the 







P-selectin is a type I transmembrane protein which is expressed on the activated 
endothelial cells. It is present in both the endothelial cells (Weibel-Palade bodies) and in 
the α-granules of platelets. P-selectin recruits leukocytes (through its P-selectin 
glycoprotein ligand-1 [PSGL-1] receptor) to the activated endothelial cells in an 
inflammatory response. Studies have shown that, like leukocytes, P-selectin can also bind 
to the platelet GPIbα. Adhesion studies carried out in the CHO (Chinese Hamster Ovary) 
cells expressing P-selectin show that these cells adhere to the immobilized GPIbα 
(glycocalicin) in a P-selectin dependent manner [17]. Thus it has been shown that the 
platelet GPIbα and P-selectin interactions may have a potential role in pathological 
conditions. 
1.3.3.5 αMβ2 
αMβ2 is a leukocyte integrin and it is also known to be a ligand for platelet 
receptor GPIbα. The αMβ2-GPIbα interaction is required for adhesion of leukocytes to 
the growing thrombus at the injured vascular bed [18]. The αMβ2-GPIbα interaction 
also facilitates physiological clearance of cold stored (<15º C) platelets. This clearing is 
due to the cold induced clustering of GPIbα which leads to clearance of platelets by 
phagocytic liver macrophages or Kupffer cells [19].  
1.3.3.6 Non-physiological GPIbα ligands 
Bacteria can bind to the platelet specific receptor GPIbα. Binding of bacteria to 
the receptor can be of physiological significance and can increase the risk of thrombosis. 
GPIbα has high amount of sialomucin. Some bacteria recognize the sialic acid by their 
cell wall proteins, e.g. Streptococcus gordonii. Some bacteria such as Staphylococcus 
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aureus, bind the GPIbα receptor by forming bridging interactions between GPIbα and 
VWF. Other bacteria bind directly to the N-terminal domain of GPIbα [12]. 
Snake venoms are also one of the non-physiological ligands of GPIbα. Snake 
venoms are complex mixtures of active proteins and peptides.  Based on their 
protein/peptide sequence, they are classified as serine proteases, metalloproteinases, C-
type lectins, disintegrins or phospholipases. They take part in hemostasis by either 
activating or inhibiting platelet functions, coagulant factor functions or disrupting the 
endothelial cells (e.g. metalloproteinases in the Crotalidae or Viperidae degrades the 
blood vessel extracellular matrix [ECM] thus affecting the haemostasis or Rhodostomin 
[a disintegrin] inhibits steps in angiogenesis and also can induce endothelial cell 
apoptosis.)The snake venoms activate platelets by activating protease receptors, or by 
binding or degrading VWF and platelet receptors or by altering the TxA2 production 
[20]. 
1.3.4. GPIb-IX-V Signaling 
Thrombus formation in vessels with high shear rates such as in arteries is 
dependent on the platelet adhesion receptor GPIb-IX-V [2, 3 and 4]. Upon vascular 
injury, the collagen in the subendothelium is exposed and circulating VWF binds to the 
collagen. VWF-GPIb initial interaction triggers GPIb dependent signaling (Fig.3) which 
results in TxA2 production. This signaling is initiated by Lyn (a tyrosine kinase), Syk (a 
cytoplasmic tyrosine kinase), SLP-76 (Src homology 2 (SH2) domain containing 
leukocyte protein76 (SLP-76), Phosphatidylinositol 3-kinase (PI3K), Bruton tyrosine 
kinase (BtK), Phospholipase Cγ2 (PLCγ2) and protein kinase C (PKC) which ultimately 
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Fig.3: GPIb-IX-V Signaling and platelet adhesion 
 
Source: J. Liu, M. Joglekar, J. Ware, M. E. C. Fitzgerald, C.A. Lowell, M. C. Berndt and 
T. K. Gartner. Evaluation of physiological significance of botrocetin/von Willebrand 
factor in vitro signaling. 2008; 6: 1915-1922. 
 
 Thus the VWF-GPIb initial interaction induces a cascade of events including 
protein phosphorylation, calcium elevation, phospholipase activation, TxA2 production 
and ADP secretion. These events lead to platelet aggregation that can be a part of normal 






Fig.4: GPIbα signaling resulting in platelet activation and aggregation. 
 
Source: J. Liu, T.I. Pestina, M.C. Berndt, S. A. Steward, C. W. Jackson and T. K. 
Gartner. The roles of ADP and TxA2 in botrocetin/VWF-induced aggregation of washed 
platelets. J Thromb Haemost. 2004; 2: 2213- 2222.   
 
 Fig.4, shows in detail the events induced by GPIbα- initiated signaling. 
Activation of GPIbα leads to thromboxane A2 (TxA2) production and secretion. TxA2 
then binds to its G-protein coupled receptor which functions through Gαq activation. Gαq 
recruits PLCβ which in turn produces inositol- trisphosphate (IP3) and diacyl glycerol 
(DAG). IP3 and DAG mobilize the intraplatelet Ca
2+ 
which in turn activates protein 
kinase C (PKC). PKC triggers dense granule secretion. ADP is released along with the 
other contents of dense granules. ADP binds to G- protein coupled P2Y1 and P2Y12 
receptors which function through Gαq and Gαi respectively. The signaling through Gαq 
further amplifies the dense granule secretion and the signaling through Gαi promotes α-
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granule secretion by inhibiting cAMP production. Fibrinogen present in the α-granules is 
released and binds to its receptor, αIIbβ3. These events lead to platelet aggregation [4]. 
1.4. von Willebrand Factor (VWF) 
 VWF is a large multimeric adhesive glycoprotein. It is present in plasma, 
endothelial cells (Weibel Palade bodies), megakaryotes, platelet α-granules and in 
connective tissue. It is secreted through constitutive and regulatory (secretory) pathways. 
It is constitutively secreted from the Weibel Palade bodies in the endothelial cells. It has 
been shown that the VWF present in plasma is structurally different from that present in 
the platelet α-granules. The platelet VWF is larger than the one present in plasma. This 
structural difference can play a specific role in normal haemostasis [21]. A mature VWF 
molecule is about residues or 275 kDa. It consists of linear sequence of modular domains 
as designated: D′-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2. The VWF in Weibel Palade 
bodies in endothelial cells is ultra-large VWF and is hyperadhesive. The ultra-large VWF 
is processed to smaller, less adhesive forms of VWF by proteolysis by (A Disintigrin and 
Metalloprotease with Thrombospondin motif) called ADAMTS13 [12]. VWF plays a role 
in normal haemostasis as it promotes platelet adhesion to the site of vascular injury and 
platelet-platelet cohesion for the thrombus growth. It is also a carrier for coagulation 
Factor VIII in plasma and protects it form proteolysis thus facilitating thrombin 
generation. The smaller VWF (multimers) are secreted in the circulation from large 
complexes of protein at the time of or after secretion from endothelial cells [12]. VWF 
acts as a major ligand for the platelet specific receptors GPIb-IX-V and αIIbβIII as shown 
in Fig.3. VWF/GPIbα interaction mediates platelet tethering to the subendothelium in 
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arteries, arterioles and venules [22], but the requirement for VWF and GPIbα in stable 
thrombus formation in veins has not been reported. 
1.5. Research Approach 
 A mouse model of ferric chloride-induced injury to the inferior vena cava (IVC) 
was used to study thrombus formation under venous shear rates. The requirements of 
platelets, the platelet specific receptor GPIbα and its ligand VWF were characterized 
using ‘knock-out’ mice. KO mice are genetically engineered mice in which a particular 
structural gene for a specific protein is subjected to a major structural alteration that 
results in permanent loss of the normal gene product. KO mice lacking the specific 
protein are used to evaluate the importance of that protein in signaling. 
Lack of thrombus formation in the knockout mice in response to FeCl3-induced injury 
shows the requirement for the missing function for a stable thrombus formation. 
1.6. Objective 
 The immediate objective of this project is to evaluate the requirements for 
platelets, the platelet specific glycoprotein Ibα receptor and VWF in FeCl3-induced stable 
thrombus formation in the mouse inferior vena cava. 
 This objective will be accomplished by completing following specific aims: 
1. Evaluate ferric chloride-induced thrombus formation in the IVC in mice with      
thrombocytopenia (22 % of the normal platelet count) induced by treatment with a 
mixture of rat anti-mouse GPIb monoclonal antibodies that elicit a rapid depletion 
of host animal’s platelets. Assuming that platelets are required for stable thrombus 
formation in IVC, Aim 2 will be completed, if not, Aim 4 will be completed in 
absence of completion of Aim 2 and 3. 
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2. Evaluate ferric chloride-induced stable thrombus formation in GPIb KO mice. 
The platelets produced in these mice lack GPIb, resulting in a condition known in 
humans as Bernard Soulier syndrome (BSS). The mice suffering from BSS 
produce abnormal platelets as a consequence of lacking GPIb. Assuming that 
GPIb is required for ferric chloride-induced stable thrombus formation in the IVC, 
Aim 3 will be completed. 
3. Evaluate FeCl3-induced stable thrombus formation in transgenic mice which lack 
murine GPIb, but express a chimeric form of human GPIb. The chimeric protein 
is designed to eliminate the extracellular domain of GPIb, without disrupting the 
normal non-stimulated function of the cytoplasmic domain of GPIb. Expression 
of transgenic GPIb mice ameliorates the abnormalities associated with the GPIb 
deficiency (BSS). 
4. Evaluate FeCl3-induced stable thrombus formation in VWF KO mice. These mice 
very closely mimic the severe or type 3 human von Willebrand disease. Type 3 
von Willebrand disease is characterized by absence of VWF in plasma, platelets, 
endothelial cells and subendothelium. Therefore these mice exhibit defects in 









CHAPTER 2: MATERIAL AND METHODS 
2.1. Animals 
Mice deficient in the platelet receptor glycoprotein Ibα, and the IL-4R/GPIb 
transgenic mice were obtained from Dr. Jerry Ware’s laboratory at the University of 
Arkansas for Medical Sciences (Little Rock, AR) [23], [24]. The IL-4R/GPIbα-tg mice 
lack murine GPIbα. They express the extracellular domain of human IL-4 receptor fused 
with the transmembrane and cytoplasmic domains of human GPIbα. The von Willebrand 
factor KO mice [25] were bred in our animal facility (University of Memphis) from 
breeding stock obtained from Jackson Laboratory, Maine. Heterozygotes of these KO 
strain have been backcrossed with C57Bl/6 mice for at least eight generations. 
2.2. Ferric chloride-induced inferior vena cava injury 
Mice were anesthetized using isofluorane (Baxter International Inc, Deerfield IL).  
The intact IVC was dissected free from surrounding tissue and placed on a paper strip 
covered with adhesive tape (13×3 mm), for support (Fig.5). Injury was induced by topical 
application of a longitudinally folded strip of Whatman No. 1 filter paper (14×3mm) 
saturated with 20% FeCl3 [26, 27] (J.T Baker Co; NJ) for 10 minutes at room 
temperature. Then the tissue was rinsed with physiological saline to remove FeCl3. Blood 
flow was monitored using a laser Doppler system with a pencil probe. Monitoring of 
blood flow lasted for 45 minutes starting at the time of the application of FeCl3. 











Fig.5: Ferric chloride-induced inferior vena cava injury. (The arrow indicates the inferior 
vena cava separated on the paper strip covered with adhesive tape).
 
2.2.1 Why ferric chloride
Ferric chloride (FeCl
The murine model for thrombus formation in response to fer
well characterized [29]. FeCl
rupturing the endothelial layer and thus exposing collagen [27]. Furthermore, thrombus 
formation in response to FeCl
stable thrombus formation was observed in mice lacking the extracellular domain of the 
platelet receptor GPIbα (which is the major ligand binding domain) after treating the 
carotid artery with 10% FeCl
formation in response to FeCl
Therefore FeCl3-induced injury model was an appropriate model to characterize the 
requirement for platelets, the platelet specific receptor GPIb




 induced injury model 
3) is often used to induce injury in mice and other animals. 
ric chloride induced injury is 
3 induces injury to the vessel by oxidizing the vessel and 
3 in the carotid artery is GPIbα-dependent [30, 31]
3 [28]. These data demonstrate that stable thrombus 
3 induced injury is GPIbα dependent in the carotid arteries. 
α and VWF in thrombus 
 
 
. Lack of 
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2.2.2 Why 20% ferric chloride 
Stable occlusion in the murine carotid artery occurs reproducibly in response to 
treatment with 10% FeCl3 for 3 minutes, with the mean time of occlusion of ~ 5.0 
minutes [28] (Fig.6A). Therefore, initially exposure to 10% ferric chloride for 3 minutes 
was used for the IVC studies. This treatment procedure did not elicit stable occlusive 
thrombi in the IVC.  None of the mice treated with 10% ferric chloride solution for 3 
minutes showed occlusion (Fig.6B). Next, the time for exposure was increased from 3 
minutes to 10 minutes keeping the concentration of FeCl3 the same (10%). The increase 
in the exposure time did not result in stable thrombus formation (Fig.7A, B). Therefore, 
the concentration of ferric chloride was increased to 20% keeping the time for exposure 
as 10 minutes. This concentration of ferric chloride resulted in complete and stable 






















Fig.6: Changes in blood flow in FeCl3 treated carotid artery (A) and inferior vena 
cava (B). 
(A): A 3 minutes treatment with 10% FeCl3 causes stable thrombus formation in a WT 
mouse within 5 minutes. 




















Fig. 8: Treatment of 20% FeCl3 to the IVC of WT mice for 10 minutes caused complete 
occlusion. 
 
Therefore treatment of the IVC with 20% ferric chloride treatment for 10 minutes 
was used for the following study. Our studies showed that 10% ferric chloride was 
sufficient to elicit the formation of stable thrombi in arteries, but was not sufficient to 
elicit stable thrombus formation in IVC. The reason(s) for this difference in response 
is/are not understood. 
2.2.3 Artery vs. Vein 
A comparison of the structural features of arteries and veins is presented because, 
it is considered that mechanism of thrombus formation in veins is essentially different 
from that in arteries. Also there is a physiological difference in between these two types 
of vessels (Fig.9). 
The walls of arteries and veins are made up of three layers which surround the lumen:  




b. Tunica media- This is the middle layer made up of circularly arranged smooth 
muscle cells and sheets of elastin. This layer is generally thicker in arteries than in 
veins.  
c. Tunica externa- This is the external layer composed of loosely meshed collagen 
fibres. These fibers protect the vessel and help in anchoring the vessels to the 
surrounding structures.  
These three layers of the vessels differ in the diameter and the thickness according to the 
type of blood vessel (arteries, arterioles, veins, venules). The shear rates in arteries and 
veins are different (Table 1). Veins have thinner elastic fiber and smooth muscle layers 
than arteries and have thin smooth muscle layer [30]. 
 
Table 1 Difference in arteries and veins [32] 
Artery 
 (Resistance Vessels) 
Vein  
(Capacitance vessels) 
Thick smooth muscle layer ( tunica media) Thin smooth muscle layer (tunica media) 
Small diameter/lumen 
Elastic artery-     1.5 cm 
Muscular artery- 6.0 mm 
Large lumen/diameter 
Vein- 5.0 mm  
High shear rates (~ 1500 sec-1) Low shear rates (50-100 sec-1) 
Muscular and thick walls; resistant to 
stretching 










Fig.9: Cross-section of IVC showing structural differences between an artery (AA
abdominal aorta) and vein (IVC
Masson’s trichrome stain. (
 
2.3. Laser flow Blood Perfusion Monitor (BMP
The laser flow blood perfusion monitor uses laser doppler technology. A low 
power beam of laser light is delivered to the tissue via a fiber optic pencil probe. The 
optic fibers in the pencil probe collect the light signals carrying information. The probe is
connected to the blood perfusion monitor which is in turn is connected to the computer. 
Graphical representation of the blood flow is obtained from the computer. The final 
results are local blood flow rates.       
2.4. Platelet depletion  
An Fc receptor-independent decrease in
injection of a mixture of rat anti
veins of mice [33].  Each isofluorane anesthetized mouse was dissected to expose the 
IVC prior to treatment (to prevent excess bleeding) 
(1µg/g of the anti-GPIbα antibody; Emfret Analytics, Germany). Monoclonal antibody 
24 
- inferior vena cava). The section was stained with 




 mouse platelets was elicited by the 
-mouse GPIb monoclonal antibodies (mab
with the anti-mouse GPIb
-
 




(mab) was injected into a tail vein.  Less than 23% of the platelets remained 15 minutes 
after injection of the antibodies (data not shown).  FeCl3 treatment of the exposed IVC 
was initiated 15 minutes after injection of the anti-GPIb antibodies.  As a negative control 
for platelet depletion, 1µg/g of non-immune rat IgG (Emfret Analytics, Germany) was 
injected in the tail vein after exposing the IVC. 
2.5. Histological studies 
For the histological studies, the tissue (IVC) was fixed in 16 % paraformaldehyde 
for 24 hours at 4ºC. The tissue was further processed by dehydrating the samples in 
increasing concentrations of ethanol (70% for 30 min, 95% 2×30 min, absolute ethanol 
3×30 min). The tissue was then cleared with xylene 3×30 min and infiltrated with 
paraffin for one hour and then embedded in paraffin blocks. Sections of tissues (5 mm 
thickness) were treated with Diffquick stain. This treatment stains platelets in a violet to 
purple color.  
2.6 Immunohistological studies 
Immunohistochemical studies were performed on the 0.5 mm thick IVC sections 
(control and IVC treated with 20% FeCl3 for 10 minutes) as directed in the protocol for 
Vectastain ABC-Alkaline phosphatase Kit (Vector Laboratories, Inc. 30 Ingold Road, 
Burlingame, CA, USA). An anti- GPIbα antibody (Emfret Analytics, Germany) was used 
as a primary antibody with (1:1000) dilution. The secondary antibody (biotinylated) was 






2.7. Statistical Analysis  
Statistical analyses were done using Chi-square test from Microsoft Office Exel, 
this involved comparison of two groups. Values of p < 0.05 are considered statistically 
significant. 
2.8. Box Plots for the murine blood flow analysis 
The box plots for the murine blood flow analysis were done using SPSS 
(Statistical Package for Social Sciences). SPSS was used for both control and KO mice. 
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CHAPTER 3: RESULTS 
3.1. FeCl3 treatment of the inferior vena cava causes platelet dependent stable 
thrombus formation.  
Stable thrombus formation can be induced in a murine carotid artery (CA) by 
treatment with FeCl3 [24, 28, 29, 34]. FeCl3-induced stable thrombus formation in the CA 
is GPIb and therefore platelet dependent [2, 24, 29]. Occlusion of blood flow as a 
consequence of FeCl3 treatment was the end point of those studies.  Platelet rich thrombi 
were shown to be the basis of occlusion of blood flow in those studies that included 
characterization of the basis of occlusion [25, 28].  Although a variety of studies 
characterizing the role of coagulation factors and their inhibitors in FeCl3-induced 
thrombus formation in mouse IVC have been described [35-37], occlusion of blood flow 
in response to thrombus formation was not monitored.  Instead, the weights of thrombi 
were measured.   
As a prelude to investigating the role of GPIb in stable thrombus formation in the 
IVC, the efficacy FeCl3 treatment as an inducer of stable, platelet-dependent thrombus 
formation in the IVC of wild type mice was characterized. In this study, the platelet 
requirement for thrombus formation was evaluated by monitoring blood flow following 
FeCl3 treatment of the IVC in the presence and absence of a mixture of purified rat anti-
mouse GPIb mabs [31]. Treatment of the circulating platelets with a mixture of 
appropriate divalent rat monoclonal anti-mouse GPIb IgG causes rapid, FcR-chain 
independent depletion of the platelets [31]. For our experiments, the mixture of IgG was 
injected into a tail vein of each anesthetized mouse after exposure of the IVC by 
dissection, and 15 minutes before treatment of the exposed IVC with 20% FeCl3. The 
28 
 
control treatment was injection of nonimmune rat IgG into the tail veins of mice 
subsequently treated with FeCl3. In contrast to the control treatment, treatment of the 
mice with the anti-GPIb mabs resulted in depletion of at least 77% of the platelets (data 
not shown) by the end of blood flow monitoring period. FeCl3 treatment of the IVC 
resulted in occlusion of blood flow in all the control animals. Five of the 7 controls 
treated with nonimmune IgG underwent total occlusion, 2 of the thrombi that caused total 
occlusion subsequently embolized prior to the end of the observation period. Two out of 
the 7 FeCl3 treated control veins underwent stable partial occlusion; that is, total 
occlusion and embolus formation did not occur during the monitoring period.  In contrast, 
the FeCl3-treated inferior vena cavae (n=7) of the mice containing the rat anti-GPIb mabs 
did not occlude (Fig. 10A).  Occlusion in the control animals (Fig.10A) was caused by 











Fig.10A: 20% FeCl3-induced IVC injury to the WT mice treated with Rat IgG (top panel) 
and anti-GPIb mab (bottom panel). (Blood flow was monitored for 45 minutes. The 
arrow represents the removal of Whatman filter paper saturated with 20% FeCl3). 
Fig.10B: Box plots of the time of occlusion for the control mice treated with non-immune 
IgG and for the mice treated with rat anti-mouse GPIb mabs. (The mean time of 
occlusion for the control mice was 25 minutes. The error bars depict the range of the time 
of occlusion for all six mice) 
 
3.2. Platelet receptor GPIbα is required for stable thrombus formation in FeCl3 
induced injury in mouse inferior vena cava 
  The data in Fig.10 demonstrate that FeCl3-induced occlusion of the IVC is platelet 
dependent.  Consequently, the role of the platelet specific receptor GPIb in FeCl3-induced 
stable thrombus formation in the IVC was investigated because the requirement for GPIb 
in venous (not venule) thrombosis has not been reported.  In order to evaluate the 
requirement of GPIb in thrombus formation in IVC, GPIb KO [21] mice were included in 
this study. In agreement with the data reported in Fig.10A, the average time to occlusion 
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for WT mice in response to FeCl3 treatment was 27 mins. In contrast, no occlusion was 
observed in any of the FeCl3 (N=6) treated GPIb KO mice (Fig. 11B),  
(P =0.00006).  Interpretation of these results was complicated by the fact that the GPIb 
KO mice exhibit platelet deficiencies similar to those of Bernard-Soulier patients [21].  
The GPIb KO mice have significantly lower than normal platelet count and the platelets 
are larger than the normal platelets (macrothrombocytopenia) [21].  So to rule out the 
possibility that the lack of occlusion in the GPIb KO mice was due to 
macrothrombocytopenia rather than the GPIb deficiency, the response of mice that do not 
express murine GPIb, but instead express the extracellular domain of the human 
interleukin-4 receptor fused with the transmembrane and cytoplasmic domains of human 
GPIb (IL-4R/GPIb-tg mice) was characterized [22]. Although these platelets lack the 
extracellular domain of GPIb, they have the normal transmembrane and cytoplasmic 
domains of human GPIb and therefore are normal in size and number.  The IVCs of the 
IL-4R/GPIb-tg mice failed to occlude (Fig.12A, bottom panel) (P = 0.00006), thereby 
demonstrating that the extracellular domain of GPIb is required for stable thrombus 


















Fig.11A: 20% FeCl3-induced IVC injury to the WT mice (top panel) and GPIb KO mice 
(bottom panel). (The arrow indicates the time of removal of the FeCl3 strip. Blood flow 
was monitored for 45 minutes) 
Fig.11B: Box plots of time of occlusion for control mice and GPIb KO mice. (The mean 



















Fig.12A: 20% FeCl3-induced IVC injury to the WT mice (top panel) and IL-4R/GPIbα-tg 
mice (bottom panel). (Blood flow was monitored for 45 minutes. The arrow indicates the 
removal of FeCl3 strip after 10 minutes). 
Fig.12B: Box plots of time of occlusion for control mice and IL-4R/GPIbα-tg mice. 
(Mean time of occlusion for the WT mice was 27 minutes). 
 
3.3. VWF is required for GPIb dependent thrombus formation in the mouse IVC. 
The paradigm for FeCl3-induced arterial thrombosis is that the process is 
mediated typically but not exclusively by GPIbα binding to VWF on the subendothelium 
exposed by damage to the endothelium [8, 23].  The data presented in Figures 11B and 
12B demonstrate that stable thrombus formation in the IVC resulting from FeCl3 
treatment is GPIb dependent.  But the requirement for VWF in this process has not been 
reported.  Accordingly, VWF deficient mice were evaluated in this system.  The effect of 
the absence of VWF was unambiguous, none of the 7 VWF KO inferior vena cavae 
formed occlusive thrombi in response to FeCl3-induced injury (Fig. 13A).  Seven VWF 
+/- (heterozygote) mice were used as controls. Out of seven, five showed occlusion and 
the remaining two showed a decrease in blood velocity but the injured IVCs did not 
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occlude completely. Lack of thrombus formation in the VWF KO mice, demonstrates that 
VWF is required for ferric chloride-induced thrombus formation under venous shear 
rates. 
 
Fig.13A: 20% FeCl3-induced IVC injury to the WT mice (top panel) and VWF KO mice 
(bottom panel). (The arrow indicated the removal of FeCl3 strip after the 10 minutes 
exposure. Blood flow was monitored for 45 minutes). 
 Fig.13B: Box plots of time of occlusion for the control mice and VWF KO mice. (The 
mean time of occlusion for the WT mice was 30 minutes). 
 
3.4. Histological and Immunohistological studies 
Thrombi formed in response to the FeCl3-induced injury to the inferior vena cavae 
were screened for the presence of platelets. In order to detect the presence of platelets in 
the occluded vessel, transverse sections of the FeCl3 treated (20% FeCl3 for 10 minutes) 




Fig.14A: 5 µm thick cross section of the control IVC treated with Diffquick stain.
(Magnification: 10 X) 
Fig.14B: IVC treated with 20% FeCl
stained with Diffquick. (The arrows in Figure B indicate the violet to purple colored 
platelets attached to the subendothelium and present in the thrombus).
(Magnification: 100 X) 
 
Trans-sections of the non
used as controls. As seen in Fig. 14B, violet to purple color stained platelets can be seen 
attached to the subendothelium and also present in the throm
platelets attached to the subendothelium support the first objective of the study by 
demonstrating that platelets are involved in the initial step of the thrombus formation in 
the IVC in response to FeCl
Immunohistochemical studies were also performed on the sections of an occluded 
IVC previously treated with 20% FeCl
receptor GPIbα were used as a marker for platelets.
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-FeCl3 treated inferior vena cavae of the WT mice were 
bus. The presence of 
3-induced injury. 





Fig.15A: 5 µm thick control IVC stained 
(Magnification: 10 X) 
Fig.15B: 5 µm thick cross section of IVC treated with 20% FeCl
stained with anti-GPIb antibody. (Arrows in Figure 14B indicate the red colored platelets 
in the thrombus and near the end
(Magnification: 100 X) 
 
As seen in Fig.15A, the control IVC is clear after staining with anti
antibody but red color stained platelets can be seen attached to the subendothelium and 
are present in the thrombus form
the hypothesis that platelets play a role in the thrombus formation in the IVC in response 







with the anti-GPIb antibody. 
3 for 10 minutes was 
othelium where injury was induced). 












CHAPTER 4: DISCUSSION 
In this study, thrombus formation in the IVC of mice in response to FeCl3-induced 
injury was characterized. The data demonstrated that FeCl3 induces thrombus formation 
in the IVC and that thrombus formation in the IVC is platelet, platelet receptor GPIbα 
and VWF dependent despite the presumptive low shear rate characteristic of the IVC. 
Thrombus formation in high shear rate vessels such as arteries and arterioles is 
platelet dependent and also requires the platelet receptor GPIbα [28]. The initial 
interaction of GPIbα with its ligand VWF is required to form the layer of platelets that 
adhere to the damaged vascular wall and provide the platelet foundation for further 
thrombus growth [20]. The thoroughly characterized FeCl3-induced injury model was 
used to study thrombus formation in arteries and arterioles [7, 30]. 
The mechanism of arterial thrombosis is considered to be essentially different 
from the bases of thrombosis in veins [38]. Venous thrombus formation is thought to 
occur on intact endothelia as a result of stasis, coagulation and fibrinolytic abnormalities, 
inflammation of the endothelium and tissue factor activity [38]. Also, venous thrombi are 
platelet-poor; and therefore some investigators feel that platelets are not required for the 
thrombus formation at venous shear rates. But in vitro platelet adhesion experiments 
using perfusion chambers have demonstrated platelet adhesion to immobilized 
fibrinogen, fibrin and VWF at low shear rates [39]. In vitro studies have also shown slow 
thrombus growth at low shear rates [13]. But in vivo studies characterizing the role of 
platelets, GPIbα, and VWF at venous shear rates have not been reported and therefore 
this study addresses this question. Previous studies were conducted on thrombus 
formation in IVC in response to FeCl3 induced injury, but those studies did not measure 
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the blood flow, instead they estimated the weight of the thrombi [33-35]. In contrast, the 
data described here demonstrate that thrombus formation, even at low shear rates as in 
IVC, in response to ferric chloride-induced injury requires platelets and GPIbα.  
The platelet requirement for the thrombus formation in the IVC in response to 
FeCl3 treatment was shown by using the mixture of rat anti-mouse GPIbα monoclonal 
antibodies (mab), known to deplete platelets rapidly [33]. None of the six mice treated 
with the mixture of mabs supported occlusion of the IVC after the FeCl3 treatment. This 
demonstrated the requirement of platelets for thrombus formation at low shear rates. 
Non-immune rat IgG was used as a control for the mab studies. Each FeCl3-treated 
(IVC)/inferior vena cavae of the WT mice showed occlusion (n= 6, mean time of 
occlusion= 25 minutes). 
  GPIb KO mice were used to evaluate the requirement of the platelet specific 
receptor GPIbα, in thrombus formation at low shear rate. These GPIb KO mice are a 
model of the human- Bernard Soulier syndrome. These mice exhibit 
macrothrombocytopenia. The inferior vena cavae of all the eight GPIb KO mice failed to 
occlude in response to FeCl3 treatment. Eight WT mice were used as controls and all of 
their (IVC/)/inferior vena cavae treated with FeCl3 occluded (mean time of occlusion- 27 
minutes). The lack of occlusion in the GPIb KO mice shows the requirement for this 
platelet receptor in thrombus formation even at venous shear rates (50 s
-1
 to 100 s
-1
).  
IL-4R/GPIbα-tg mice were studied to show the requirement of the extracellular domain 
of GPIb, and thus to rule out the possibility that the lack of thrombus formation in GPIb 
KO mice was due to the macrothrombocytopenia. The IL-4R/GPIbα-tg mice lack murine 
GPIb, but have the extracellular domain of the human IL-4R fused with transmembrane 
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and cytoplasmic domain of human- GPIb. The cytoplasmic domain of this chimeric 
protein ameliorates the macrothrombocytopenia, but the protein still lacks the 
extracellular domain of GPIbα. No occlusion was observed in each of the eight IL-
4R/GPIbα-transgenic mice IVC studied. In contrast, each FeCl3 treated IVC of the WT 
mice showed occlusion (mean time= 27 minutes). So although previous studies have 
shown that thrombus formation in response to ferric chloride-induced injury in venules 
(shear rate- 150 s
-1
 to 200 s
-1
) is GPIbα independent [7], our data demonstrate and 
confirm the requirement of the extracellular domain of GPIbα for thrombus formation 
after ferric chloride treatment of the murine IVC. 
VWF is the major ligand for the platelet receptor GPIb and their interaction is a 
requirement for thrombus formation in high shear rate vessels [3]. But previous studies 
carried out in high shear rate vessels such as arterioles, have found that the thrombus 
formation after FeCl3-induced injury does not absolutely require VWF [8]. So we studied 
the requirement for VWF in thrombus formation at venous shear rates. In vitro adhesion 
studies have shown that platelets can adhere to VWF at low shear rates [9]. But the in 
vivo requirement of VWF at venous shear rates in response to ferric chloride induced 
injury had not been reported/characterized prior to our study. We used VWF KO mice to 
study the thrombus formation in response to FeCl3-induced injury to the IVC. VWF +/- 
mice were used as controls. Out of the seven VWF KO mice, none showed occlusion of 
the IVC. In contrast all the WT mice occluded within 30 minutes (mean time of 
occlusion). Thus our data demonstrate an absolute requirement of VWF for thrombus 
formation in the IVC. 
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Pulmonary embolism is the result of unstable thrombi in veins. Characterization 
of thrombus formation in carotid arteries revealed stable GPIb/VWF dependent thrombus 
formation in response to FeCl3-induced injury. Embolization did not occur throughout the 
duration of observation period [30]. In contrast, thrombi in the occluded IVC embolized 
frequently. This difference in stability of the thrombi formed in arteries and veins may be 
the function of blood shear rate in veins and the physiological differences between 
arteries and veins. But experiments testing this concept have not been done at the 
physiological shear rates [40]. And so the reason for the embolization characteristic of the 
venous thrombosis is not understood and remains unclear.  
To summarize, our studies demonstrate that FeCl3-induced thrombus formation 
occurs in the IVC of the mouse in a platelet, GPIb and VWF-dependent manner, despite 
the large diameter and the venous shear rate of the IVC.  These results support the 
hypothesis that platelets can play an important role in DVT and VTE despite the low 












CHAPTER 5: CONCLUSION 
Thrombus formation in the mouse inferior vena cava in response to FeCl3- 
induced injury was characterized. The thrombus formation in the inferior vena cava was 
platelet, platelet-specific receptor GPIb and VWF dependent. This study demonstrated 
that stable thrombus formation can occur in a large vein with a low shear rate in a 
platelet, glycoprotein Ib-IX and VWF-dependent manner.  



















CHAPTER 6: FUTURE SCOPE 
The following next steps are required for this research: 
1. Thrombus formation in IVC in response to 20% FeCl3-induced injury 
characterized in αIIbβ3 KO mice to study the importance of this receptor in thrombus 
growth and stability at venous shear rates as being another important and abundant 
receptor on the platelet membrane. 
2. Thrombus formation under more physiological conditions should be 
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